PACS Group, Inc. (PACS) — the peer cohort

As of 2026-10-08 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

PACS Group, Inc. ranks 5 of 8 in its cohort on the Closelooknet composite (54/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

Name	Composite	Momentum	Quality	Valuation	Signal	Off 52w high
PACS PACS Group, Inc.	54	72	40	56	ok	11.6%
FMS Fresenius Medical Care Corporation	50	34	36	84	info	21.4%
ENSG The Ensign Group Inc	48	37	36	45	warn	21.3%
RHC.AU Ramsay Health Care Ltd	45	91	23	54	ok	2.6%
HALO Halozyme Therapeutics Inc	74	94	94	51	ok	6%
DXCM DexCom Inc	66	83	80	37	watch	9%
ONC BeiGene, Ltd.	64	77	64	32	info	9.1%
MEDP Medpace Holdings Inc	63	82	75	30	ok	11.1%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-08

Quick answers

Who are PACS Group, Inc.'s peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Fresenius Medical Care Corporation (FMS), The Ensign Group Inc (ENSG), Ramsay Health Care Ltd (RHC.AU), Halozyme Therapeutics Inc (HALO), DexCom Inc (DXCM), BeiGene, Ltd. (ONC), Medpace Holdings Inc (MEDP).

How does PACS score against its peers?

PACS Group, Inc.'s composite reads 54/100, ranking 5 of 8 in its cohort as of 2026-10-08; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Medical Care Facilities, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.